Agenus Inc. (Nasdaq: AGEN), an immuno-oncology company developing a
portfolio of checkpoint modulators (CPMs), heat shock protein vaccines
and adjuvants, today announced that Robert Stein, MD, PhD, the company’s
Chief Scientific Officer, is scheduled to present a company overview at
the Jefferies 2014 Global Healthcare Conference in New York City on
Thursday, June 5th at 1:00 pm ET.
Web Cast Information
The live and archived webcast of the company presentation will be
accessible from the company’s website at www.agenusbio.com/webcast.
Please log in approximately 5-10 minutes before each event to ensure a
timely connection. The archived replay will be available on the Agenus
website for one month following the conference.
About Agenus
Agenus is an immuno-oncology company developing a portfolio of
checkpoint modulators (CPMs), heat shock protein vaccines and adjuvants.
Agenus’ checkpoint modulator programs target GITR, OX40, CTLA-4, LAG-3,
TIM-3 and PD-1. The company’s proprietary discovery engine Retrocyte
Display® is used to generate fully human therapeutic antibody
drug candidates. The Retrocyte Display platform uses a high-throughput
approach incorporating IgG format human antibody libraries expressed in
mammalian B-lineage cells. Agenus’ heat shock protein vaccines for
cancer and infectious disease are in Phase 2 studies. The company’s
QS-21 Stimulon® adjuvant platform is extensively partnered
with GlaxoSmithKline and Janssen and includes several candidates in
Phase 3 trials. Among Agenus and its partners, 22 programs are in
clinical development. For more information, please visit www.agenusbio.com,
or connect with the company on Facebook, LinkedIn, Twitter and Google+.
For more information, please visit www.agenusbio.com.
Forward-Looking Statement
This press release contains forward-looking statements, including
statements regarding corporate presentations, research, development and
clinical trial activities, and the potential application of the
Company’s technologies and product candidates in the prevention and
treatment of diseases. These forward-looking statements are subject to
risks and uncertainties that could cause actual results to differ
materially. These risks and uncertainties include, among others, the
factors described under the Risk Factors section of our Quarterly Report
on Form 10-Q filed with the Securities and Exchange Commission for the
period ended March 31, 2014. Agenus cautions investors not to place
considerable reliance on the forward-looking statements contained in
this release. These statements speak only as of the date of this
document, and Agenus undertakes no obligation to update or revise the
statements. All forward-looking statements are expressly qualified in
their entirety by this cautionary statement. Agenus’ business is subject
to substantial risks and uncertainties, including those identified
above. When evaluating Agenus’ business and securities, investors should
give careful consideration to these risks and uncertainties.
Copyright Business Wire 2014